These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9303393)

  • 1. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.
    Krishnarao TV; Galgiani JN
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1957-60. PubMed ID: 9303393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans.
    Ernst EJ; Klepser ME; Pfaller MA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
    Roling EE; Klepser ME; Wasson A; Lewis RE; Ernst EJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 May; 43(1):13-7. PubMed ID: 12052624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
    Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S
    Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
    Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
    J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
    Franzot SP; Casadevall A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
    Pfaller MA; Diekema DJ; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1068-71. PubMed ID: 12604543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.
    Barchiesi F; Schimizzi AM; Fothergill AW; Scalise G; Rinaldi MG
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):302-4. PubMed ID: 10385023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
    Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
    J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.
    Pfaller MA; Marco F; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 1998 Apr; 30(4):251-5. PubMed ID: 9582584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
    Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
    J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.
    Del Poeta M; Cruz MC; Cardenas ME; Perfect JR; Heitman J
    Antimicrob Agents Chemother; 2000 Mar; 44(3):739-46. PubMed ID: 10681348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates.
    To WK; Fothergill AW; Rinaldi MG
    J Clin Microbiol; 1995 Oct; 33(10):2660-4. PubMed ID: 8567901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.
    van Duin D; Casadevall A; Nosanchuk JD
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3394-400. PubMed ID: 12384341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
    Espinel-Ingroff A; Canton E; Gibbs D; Wang A
    J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.